JCM Figure table search 04
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ornstein, K.
Right arrow Articles by Bergström, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ornstein, K.
Right arrow Articles by Bergström, S.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, April 2001, p. 1294-1298, Vol. 39, No. 4
0095-1137/01/$04.00+0   DOI: 10.1128/JCM.39.4.1294-1298.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

Characterization of Lyme Borreliosis Isolates from Patients with Erythema Migrans and Neuroborreliosis in Southern Sweden

Katharina Ornstein,1 Johan Berglund,1 Ingrid Nilsson,1 Ragnar Norrby,1 and Sven Bergström2,*

Department of Infectious Diseases and Medical Microbiology, Lund University, Lund,1 and Department of Microbiology, Umeå University, Umeå,2 Sweden

Received 16 August 2000/Returned for modification 11 November 2000/Accepted 11 January 2001


    ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

Southern Sweden is an area of Lyme borreliosis (LB) endemicity, with an incidence of 69 cases per 100,000 inhabitants. The most frequent clinical manifestations are erythema migrans (77%) and neuroborreliosis (16%). There was no record of human Borrelia strains being isolated from patients in this region before the prospective study reported here. Borrelia spirochetes were isolated from skin and cerebrospinal fluid (CSF) from LB patients living in the region. A total of 39 strains were characterized by OspA serotype analysis, species-specific PCR, and signature nucleotide analysis of the 16S rRNA gene. Of 33 skin isolates, 31 (93.9%) were Borrelia afzelii strains and 2 (6.1%) were Borrelia garinii strains. Of six CSF isolates, five (83.3%) were B. garinii and one (16.7%) was B. afzelii. Neither Borrelia burgdorferi sensu stricto strains nor multiple infections were observed. The B. afzelii isolates were of OspA serotype 2. Three B. garinii strains were of OspA serotype 5, and the remaining four strains were of OspA serotype 6. All of the B. garinii strains belonged to the same 16S ribosomal DNA ribotype class. Our findings agree with earlier findings from other geographic regions in Europe where B. afzelii and B. garinii have been recovered predominately from skin and CSF cultures, respectively. To further study the possible presence in Sweden of the genotype B. burgdorferi sensu stricto, which is known to be present in Europe and to occur predominately in patients with Lyme arthritis, molecular detection of Borrelia-specific DNA in synovial samples from Lyme arthritis patients should be performed.


    INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

Lyme borreliosis (LB) or Lyme disease (15) is probably the most common tick-borne human disease in Europe and the United States. The disease is a multisystemic infection caused by the tick-borne spirochete Borrelia burgdorferi sensu lato. Cases of LB and isolates of spirochetes have been identified in most countries in the Northern Hemisphere (1, 6, 12, 17, 20). The distribution of the disease is associated with the distribution of the Ixodes tick complex and, in Europe, Ixodes ricinus (26). This tick is known to be abundant especially in the southern coastal areas and central regions of Sweden, with a 5 to 26% prevalence of borrelia-infected ticks (11, 12, 23). Typical borrelial infections primarily involve the skin, nervous system, and joints. Involvement of the nervous system neuroborreliosis is the predominant result of morbidity caused by the Borrelia bacteria in Europe, and Borrelia bacteria are also the most common bacterial pathogen of the nervous system in Sweden (43).

Borrelia isolates that cause LB are divided into three different genospecies of the B. burgdorferi sensu lato group, B. burgdorferi sensu stricto, Borrelia afzelii, and Borellia garinii, on the basis of DNA sequence identity (6, 18, 46). However, human pathogenic Borrelia species that cannot be classified into any of these groups have recently been reported (45). The three B. burgdorferi sensu lato genospecies have been isolated from human skin, cerebrospinal fluid (CSF), and synovial fluid as well as from ticks in Europe (16, 17, 22, 25), whereas only the B. burgdorferi sensu stricto genotype has been found in humans in North America. The agents of LB are divided into eight serotypes based on their reactivity to OspA monoclonal antibodies (MAbs) (47, 48). Furthermore, clinical data suggest an association between infecting Borrelia species and clinical manifestations in Europe (4, 5, 16, 17, 21, 22, 27, 39, 40, 44). B. burgdorferi sensu stricto is the most common spirochete species associated with Lyme arthritis, and B. afzelii predominates in the skin, especially in cases of acrodermatitis chronica atrophicans (ACA) (39). B. garinii is most often associated with neuroborreliosis (5, 44). Most European skin isolates belong to OspA serotype 2 of B. afzelii, whereas a similar but less-stringent association has emerged between CSF isolates and B. garinii (47).

Southern Sweden has been identified as an area where LB is highly endemic, with an incidence of 69 cases per 100,000 inhabitants (10). The most frequent clinical manifestations are erythema migrans (EM) (77%), neuroborreliosis (16%), and arthritis (7%). No LB isolates had been recovered in this area of endemicity before our present study.

The aim of this study was to isolate and characterize the Borrelia species that cause LB in southern Sweden. LB isolates were recovered from skin and CSF. The isolated strains were characterized by species-specific PCR, signature nucleotide analysis by partial 16S rRNA gene sequencing (14, 34), and tests of immune reactivity to a panel of MAbs directed against OspA (47, 48).


    MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

Study population. This prospective multicenter study was carried out at eight different locations in southern Sweden, an area where LB is endemic, from 1994 to 1997. Patients suspected of having EM and neuroborreliosis were studied. Only adults were included in the group that had skin biopsies. The ethics committee of Lund University, Lund, Sweden, approved the study. The departments involved in this study were the departments of infectious diseases, pediatrics, and dermatology at local hospitals in southern Sweden in the provinces of Skåne, Blekinge, Halland, and Kalmar, and an outpatient primary care center in the province of Blekinge.

Culture of Borrelia spp. Borrelia spirochetes were cultured from 4-mm skin biopsy specimens and 1-ml CSF samples in Barbour-Stoenner-Kelly medium II (7), with 10% rabbit sera (Sigma Chemical Co., St. Louis, Mo.) and 1.3% Bacto gelatin (Difco Laboratories, Detroit, Mich.). The medium used for skin biopsy specimens contained 100 µg of fosfomycin (Sigma) per ml and 50 µg of rifampicin (Sigma) per ml to inhibit the growth of contaminating microorganisms. Cultures were incubated at 32°C, and growth was recorded weekly using dark-field microscopy. The reference strains used were B. burgdorferi sensu stricto B31 (ATCC 35210) (15), a North American tick isolate; ACA1 B. afzelii, isolated from a Swedish ACA patient (2); and an IP90 B. garinii tick isolate from Russia (29).

OspA serotyping. All of the local isolates used for protein analysis were low-passage strains (<10 passages), and the cells were grown in Barbour-Stoenner-Kelly medium II until middle to late log phase. Sonicated whole-cell lysates prepared from Borrelia cells were separated on a sodium dodecyl sulfate-polyacrylamide gel electrophoresis 4 to 15% gradient gel (Bio-Rad, Richmond, Calif.), and the proteins were transferred to polyvinylidene difluoride membranes (0.45-µm pore size; MSI Inc., Westborough, Mass.), as previously described (37). These membranes were probed with a panel of eight OspA MAbs (47, 48), including L32-1F11, L32-1C8, L32-14G7, L32-1G3, L32-1F7, and L32-1D11, which were provided by B. Wilske, and H5332 and H3TS (8), which were obtained from A. G. Barbour. The H3TS is type-specific for B. burgdorferi sensu stricto serotype 1, and L32-14G7 is type-specific for B. afzelii serotype 2. B. garinii shows a more divergent pattern that is covered by serotypes 3 to 8.

Genotyping: 16S rRNA gene (16S rDNA) analysis. DNA was isolated according to the method of Bunikis et al. (14). Standard PCR routines were used to prevent contamination (30). Briefly, filter tips (ART, San Diego, Calif.) were used, and amplified Borrelia DNA was handled in a different location. Contamination controls included extraction controls and negative buffer controls in parallel with strain samples. Genospecies-specific identification of LB isolates was determined by 16S rRNA gene analysis using PCR and primers described by Marconi and Garon (34): a (LD) primer set specific for B. burgdorferi sensu lato, a (BB) primer set genospecific for B. burgdorferi sensu stricto, a (BA) primer set genospecific for B. afzelii, and a (BG) primer set genospecific for B. garinii. Primers were synthesized by Interactiva Biotechnologie GmBh, Ulm, Germany. PCR mixtures contained a 0.2 µM concentration of each primer, and the PCR buffer solution contained 10 mM Tris-HCl, 1.5 mM MgCl, 50 mM KCl (pH 8.3), 0.2 mM concentrations of each deoxynucleoside triphosphate, and 1 U of Taq DNA polymerase (Boehringer Mannheim, Mannheim, Germany). PCRs were performed in an MJ PTC-100 thermocycler (MJ Research Inc., Waltham, Mass.), as previously described (34). The amplified DNA was separated by agarose gel electrophoresis, stained by ethidium bromide, and visualized using a standard UV transilluminator.

The PCR products were purified in MicroSpin Columns S-400 (Pharmacia Biotech, Uppsala, Sweden) prior to sequencing. Cycle sequencing was carried out using the PCR species-specific primers in an ABI PRISM rhodamine dye terminator cycle sequencing core kit with AmpliTaq DNA Polymerase FS (PE Applied Biosystems, Foster City, Calif.). The cycle-sequencing products were purified in MicroSpin S-200 Columns (Pharmacia Biotech) before being analyzed on an automatic sequencer (ABI PRISM 373A; PE Applied Biosystems). Sequences used for comparison were B. burgdorferi sensu stricto strain B31, B. afzelii strain DK4, and B. garinii strain IP90 (accession numbers UO3396, X85194, and M89937, respectively). Analysis of signature nucleotides was performed as described earlier (34), using the software BioEdit version 4.8.6 (Tom Hall, Department of Microbiology, North Carolina State University, Raleigh, N.C.)


    RESULTS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

Isolation of local human pathogen spirochetes. Seventy-nine skin biopsy specimens and 207 CSF cultures from suspected LB cases were included in the study. Seventy-five patients with EM fulfilled the Centers for Disease Control and Prevention (CDC) criteria for Lyme disease (19), with the exception that a skin lesion less than 5 cm in size was accepted. Four skin biopsy specimens were taken from patients who were considered not to have EM. Thirty-three strains were collected from the 75 skin biopsy specimens, which was a success rate of 42%. The skin strains were recovered from biopsy specimens from individuals whose ages ranged from 19 to 69 years. The female/male distribution was 16:17. Twelve patients with EM had general symptoms of disseminated LB with low-grade fever, headache, arthralgia, and myalgia, and one patient had concomitant meningitis (LU253).

Eighty of the 207 patients included in the study fulfilled the CDC criteria for neuroborreliosis (19). Of these patients, 10 did not have meningitis. Six CSF isolates were recovered from the 70 patients with meningitis who also fulfilled the CDC criteria for neuroborreliosis, which results in an 8.6% culture success rate. The CSF strains were all obtained from children with meningitis who ranged from 4 to 7 years of age. In addition, two of six children had meningitis and facial palsy. Three of the six children presented an EM or had a history of EM in the head region.

When contamination and the number of patients that were treated with an antibiotic before sampling were considered, the success rates for culturing EM skin biopsy specimens and CSF were 50% and 10.2%, respectively.

The 33 isolates originating from skin biopsy specimens from patients with EM were identified as LU30, LU34, LU35, LU54, LU58, LU65, LU68, LU71, LU72, LU81, LU82, LU85, LU116, LU118, LU156, LU157, LU165, LU169, LU171, LU182, LU188, LU192, LU203, LU207, LU209, LU212, LU215, LU218, LU235, LU253, LU254, LU256, and LU9038. The six CSF isolates are identified as LU59, LU170, LU185, LU190, LU216, and LU222.

OspA serotyping. The results of the OspA serotyping are shown in Table 1. Three isolates were contaminated (LU34, LU35, and LU182) and therefore could not be used for specific protein analysis. Two strains could not be subcultured (LU30 and LU65), and only enough cells for DNA analysis were obtained. None of the strains showed any reactivity to the MAb H3TS that is type specific for B. burgdorferi sensu stricto and represents the OspA serotype 1. Twenty-six of the 28 strains (92.9%) isolated from skin and 1 of the 6 strains (16.7%) isolated from CSF reacted with the MAb L32-14G7 that is type specific for B. afzelii and represents OspA serotype 2. One of the skin strains (LU116) and two of the six strains isolated from CSF (LU59 and LU170) were classified as B. garinii OspA serotype 5. One of the skin strains (LU118) and three of the six strains isolated from CSF (LU185, LU190, and LU222) reacted as B. garinii OspA serotype 6. 

                              
View this table:
[in this window]
[in a new window]
  		TABLE 1.   Immunoreactivity of B. burgdorferi sensu lato strains with a panel of OspA-specific MAbs

16S rDNA PCR and 16S rDNA signature nucleotide analysis. The results of the species-specific PCRs are summarized in Table 2. All of the locally isolated strains could be amplified using the B. burgdorferi sensu lato-specific primer set LD, whereas none of the local strains could be amplified by the B. burgdorferi sensu stricto primer set BB. The DNA from 31 of 33 strains isolated from skin (93.9%) and 1 of 6 strains from CSF (16.7%) was amplified by the species-specific primer pair for B. afzelii (BA). Two of 33 strains originating from skin (6.1%) and 5 of 6 strains isolated from CSF (83.3%) were amplified with the species-specific primer pair for B. garinii (BG). None of the local isolates were amplified by both BA and BG primer sets.

                              
View this table:
[in this window]
[in a new window]
  		TABLE 2.   Summary of species-specific PCR

The 16S rDNA signature nucleotide analysis was performed by partial sequencing of the 16S rRNA gene using the subspecies-specific primer pairs used in the PCR. The results of the signature nucleotide analysis are shown in Table 3. Thirty-one of the 33 skin strains and 1 of the 6 CSF strains amplified and sequenced with the BA species-specific primer pair demonstrated the same signature nucleotide pattern as B. afzelii reference strain DK4. All of the B. garinii strains isolated, two from skin and five from CSF, that were amplified and sequenced with the BG species-specific primer pair showed the same pattern as reference strain IP90, a B. garinii strain ribotype 1. 

                              
View this table:
[in this window]
[in a new window]
  		TABLE 3.   Analysis of signature nucleotide positions of the partial 16S rDNA in studied Borrelia strains


    DISCUSSION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

In this prospective study we have for the first time recovered and characterized Borrelia strains from humans with LB in southern Sweden, an area where the high endemicity of LB is well defined (10).

The genospecies that we found to predominate in early skin borreliosis was B. afzelii (93.9%), while B. garinii predominated in neuroborreliosis (16.7%). Few B. garinii strains were recovered from skin. Occasionally, the B. afzelii strain was recovered from CSF, and one patient with EM and concomitant meningitis had a B. afzelii-positive skin culture. The three different methods used for genospecies determination, 16S rDNA PCR, signal nucleotide analysis, and OspA serotyping, all showed the same results. Our findings are in concordance with earlier clinical studies in Europe (4, 5, 16, 21, 22, 39, 44). B. garinii and B. afzelii have also previously been recovered from skin and CSF in other geographic regions in Sweden (2, 3, 6, 16, 28, 31).

B. garinii has previously been shown to form three patterns of variable signal nucleotide positions in the partial 16S rDNA sequence (14). All of the B. garinii isolates in this study fell into the 16S rDNA signal nucleotide pattern seen in the Russian tick isolate B. garinii IP90 ribotype 1. The B. garinii isolates diverged into the two OspA serotypes 5 and 6. OspA serotype 6 has been shown to predominate in CSF isolates from children in Germany (47). The diversity of B. garinii OspA serotypes depends on the geographical distribution of LB strains (16, 17, 47, 48). Comparison of B. garinii OspA serotypes from tick isolates in Japan with B. garinii serotypes isolated in Europe shows that different OspA serotypes exist on these two continents as well (35).

The B. burgdorferi sensu stricto genotype has yet to be isolated in Sweden from humans, nor have B. burgdorferi sensu stricto genotypes been found among isolates from our patients. This genotype was isolated from a lesion from a patient with ACA (31) in neighboring Denmark and was also identified by DNA analysis in I. ricinus ticks that were collected from migrating birds in southern Sweden (38). B. burgdorferi sensu stricto is known to be present in European LB, and it has been recovered from both skin and CSF but has been found more often than B. afzelii and B. garinii in synovial samples when molecular analytical methods are used (22, 25, 27). Detection of Borrelia-specific DNA in synovial samples from Lyme arthritis patients should be performed in Sweden to examine the possible presence of the genotype B. burgdorferi sensu stricto in LB.

We did not identify any multiple infections of the various genospecies in our human LB isolates. Mixed infections and genetic diversity of B. burgdorferi sensu lato, as determined by culture and/or PCR, have been observed both in Europe and the United States (20, 32, 33). The possibility of identifying multiple infections probably depends on both variation in growth requirements and factors such as the origin of the spirochetes and the technique and method being used.

Isolation of B. burgdorferi by culture is the best diagnostic evidence of LB. The bacteria are not easily recovered from clinical specimens other than biopsy samples from EM lesions. A success rate of more than 80% with skin biopsy specimens from EM patients has been reported (9). Our success rate was lower, partly due to specimen contamination and antibiotic treatment of patients prior to sampling. All of the CSF isolates were recovered from children who contracted neuroborreliosis less than 3 weeks after subclinical symptoms of meningitis or an acute facial palsy were diagnosed. Adults seem to have a tendency to neglect their symptoms, as many delayed seeing a doctor for more than 3 weeks after onset of symptoms, which may have decreased the possibility of recovering Borrelia spp. from CSF. The Borrelia medium used to culture skin biopsy specimens was supplemented with antibiotics, while the medium for CSF was antibiotic-free, which may have influenced the growth of B. garinii in CSF.

Culture is generally not useful for detection of the Borrelia bacteria or confirmation of the LB diagnosis. For laboratory diagnosis of LB, the enzyme-linked immunosorbent assay and Western blot usually are used. The importance of different B. burgdorferi species used in the antigenic preparations for these tests has been studied in LB patients in Germany (24). Results from the present study indicate a variation in test results that favors a locally recovered Borrelia strain due to the different levels of expression of immunodominant proteins. Use of local LB strains, together with information on the seroreactivity in the population to be tested, should be taken into account when developing diagnostic serological assays for clinical diagnosis (13, 36).

Two B. burgdorferi sensu stricto OspA-based Borrelia vaccines have been developed (41, 42). The geographic diversity and the wide range of clinical manifestations found in European B. burgdorferi sensu lato strains present a great challenge for vaccine development. A prerequisite for developing an LB vaccine is access to a variety of microbiologically and clinically well-characterized Borrelia strains.

Our results confirm the presence of B. afzelii and B. garinii in LB in Sweden. Additional studies on synovial samples from Lyme arthritis with molecular methods would be interesting in order to explore the possible presence of the genotype B. burgdorferi sensu stricto in Sweden. An effective Borrelia vaccine for Sweden at the minimum should protect against infection with the two genospecies B. afzelii and B. garinii.


    ACKNOWLEDGMENTS

This work was supported by grants from the Swedish Medical Research Council (grants 07922 and 04723), the University Hospital of Lund, the medical faculty of Lund University Kungliga Fysiografiska Sällskapet i Lund, Thelma Zoegas and Johanissons Stiftelse.

We thank Bettina Wilske for MAbs L32 1F11, L32 1C8, L32 14G7, L32 1G3, L32 1F7, and L32 1D11 and Alan Barbour for MAbs H5332 and H3TS and for reviewing the manuscript. We express our appreciation to the clinics taking part in this study: Infectious Diseases, Pediatrics, and Dermatology at the University Hospital in Lund and the hospital in Helsingborg; and Infectious Diseases and Pediatrics at the University Hospital in Malmö, the hospital in Kristianstad, the hospital in Halmstad, the hospital in Karlskrona, and the Kalmar County Hospital and the Ronneby Primary Care Clinic in Blekinge Province.


    FOOTNOTES

* Corresponding author. Mailing address: Department of Microbiology, Umeå University, S-901 87 Umeå, Sweden. Phone: 46-(0)90-7856726. Fax: 46-(0)90-772630. E-mail: sven.bergstrom{at}micro.umu.se.


    REFERENCES
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

1. Adam, T., G. S. Gassman, C. Rasiah, and U. B. Göbel. 1991. Phenotypic and genotypic analysis of Borrelia burgdorferi isolates from various sources. Infect. Immun. 59:2579-2585.
2. Åsbrink, E., A. Hovmark, and B. Hederstedt. 1984. The spirochetal etiology of acrodermatitis chronica atrophicans Herxheimer. Acta Dermatol. Venereol. 64:506-512[Medline].
3. Åsbrink, E., and A. Hovmark. 1984. Successful cultivation of spirochetes from skin lesions of patients with erythema chronicum migrans and Afzelius acrodermatitis chronica atrophicans. Acta Pathol. Microbiol. Immunol. Scand. Sect. B 93:161-163.
4. Assous, M. V., D. Postic, G. Paul, P. Névot, and G. Baranton. 1993. Western blot analysis of sera from Lyme borreliosis patients according to the genomic species of the Borrelia strains used as antigens. Eur. J. Clin. Microbiol. Infect. Dis. 12:261-268[CrossRef][Medline].
5. Balmelli, T., and J. C. Piffaretti. 1995. Association between different clinical manifestations of Lyme disease and different species of Borrelia burgdorferi sensu lato. Res. Microbiol. 146:329-340[Medline].
6. Baranton, G., D. Postic, I. Saint Girons, P. Boerlin, J.-C. Piffaretti, M. Assous, and P. A. Grimont. 1992. Delineation of Borrelia burgdorferi sensu stricto, Borrelia garinii sp. nov., and group VS461 associated with Lyme borreliosis. Int. J. Bacteriol. 42:378-383[Abstract/Free Full Text].
7. Barbour, A. G. 1984. Isolation and cultivation of Lyme disease spirochetes. Yale J. Biol. Med. 57:521-525[Medline].
8. Barbour, A. G., S. L. Tessier, and W. J. Todd. 1983. Lyme disease spirochetes and ixodid tick spirochetes share a common surface antigenic determinant defined by a monoclonal antibody. Infect. Immun. 41:795-804[Abstract/Free Full Text].
9. Berger, B. W., R. C. Johnson, C. Kodner, and L. Coleman. 1992. Cultivation of Borrelia burgdorferi from erythema migrans lesions and perilesional skin. J. Clin. Microbiol. 30:359-361[Abstract/Free Full Text].
10. Berglund, J., R. Eitrem, K. Ornstein, A. Lindberg, Å. Ringnér, H. Elmrud, M. Carlsson, A. Runehagen, C. Svanborg, and R. Norrby. 1995. An epidemiological study of Lyme disease in southern Sweden. N. Engl. J. Med. 333:1319-1324[Abstract/Free Full Text].
11. Berglund, J., and R. Eitrem. 1993. Tick-borne borreliosis of the archipelago of southern Sweden. Scand. J. Infect. Dis. 25:67-72[Medline].
12. Bergström, S., B. Olsen, N. Burman, L. Gothefors, T. G. T. Jaenson, M. Jonsson, and H. Mejlon. 1992. Molecular characterization of Borrelia burgdorferi isolated from Ixodes ricinus in northern Sweden. Scand. J. Infect. Dis. 24:181-188[Medline].
13. Bunikis, J., B. Olsén, G. Westman, and S. Bergström. 1995. Variable serum immunoglobulin responses against different Borrelia burgdorferi sensu lato species in a population at risk for and patients with Lyme disease. 33:1473-1478.
14. Bunikis, J., B. Olsén, V. Fingerle, J. Bonnedahl, B. Wilske, and S. Bergström. 1996. Molecular polymorphism of the Lyme disease agent Borrelia garinii in northern Europe is influenced by a novel enzootic Borrelia focus in the North Atlantic. J. Clin. Microbiol. 34:364-368[Abstract].
15. Burgdorfer, W., A. G. Barbour, S. F. Hayes, J. L. Benach, E. Grunwaldt, and J. P. Davis. 1982. Lyme disease---a tick-borne spirochetosis? Science 216:1317-1319[Abstract/Free Full Text].
16. Busch, U., C. Hizo-Teufel, R. Böhmer, D. Rößler, V. Fingerle, H. Nitschko, B. Wilske, and V. Preac Mursic. 1996. Three species of Borrelia burgdorferi sensu lato (B. burgdorferi sensu stricto, B. afzelii, and B. garinii) identified from cerebrospinal fluid isolates by pulsed-field gel electrophoresis and PCR. J. Clin. Microbiol. 34:1072-1078[Abstract].
17. Busch, U., C. Hizo-Teufel, R. Böhmer, V. Fingerle, D. Rößler, B. Wilske, and V. Preac Mursic. 1996. Borrelia burgdorferi sensu lato strains isolated from cutaneous Lyme borreliosis biopsies differentiated by pulsed-field gel electrophoresis. Scand. J. Infect. Dis. 28:583-589[Medline].
18. Canica, M. M., F. Nato, I. du Merle, J. C. Mazie, G. Baranton, and D. Postic. 1993. Monoclonal antibodies for identification of Borrelia afzelii sp. nov. associated with late cutaneous manifestations of Lyme borreliosis. Scand. J. Infect. Dis. 25:441-448[Medline].
19. Centers for Disease Control. 1990. Case definitions for public health surveillance. Morb. Mortal. Wkly. Rep. 39(RR-13):19[Medline].
20. Demarschalck, I., A. Ben Messaoud, M. De Kesel, B. Hoyois, Y. Lobet, P. Hoet, G. Bigaignon, A. Bollen, and E. Godfroid. 1995. Simultaneous presence of different Borrelia burgdorferi genospecies in biological fluids of Lyme disease patients. J. Clin. Microbiol. 33:602-608[Abstract].
21. Dressler, F., R. Ackermann, and A. C. Steere. 1994. Antibody responses to the three genomic groups of Borrelia burgdorferi in European Lyme borreliosis. J. Infect. Dis. 169:313-318[Medline].
22. Eiffert, H., A. Karsten, R. Thomssen, and H. J. Christen. 1998. Characterization of Borrelia burgdorferi strains in Lyme arthritis. Scand. J. Infect. Dis. 30:265-268[CrossRef][Medline].
23. Gustavsson, R., T. Jaenson, A. Gardulf, H. Mejlon, and B. Svenungsson. 1995. Prevalence of ticks infected with Borrelia spirochetes in Sweden. Scand. J. Infect. Dis. 27:597-601[Medline].
24. Hauser, U., H. Krahl, H. Peters, V. Fingerle, and B. Wilske. 1998. Impact of strain heterogeneity on Lyme disease serology in Europe: comparison of enzyme-linked immunosorbent assays using different species of Borrelia burgdorferi sensu lato. J. Clin. Microbiol. 36:427-436[Abstract/Free Full Text].
25. Hubalek, Z., and J. Halouzka. 1997. Distribution of Borrelia burgdorferi sensu lato groups in Europe, a review. Eur. J. Epidemiol. 13:951-957[CrossRef][Medline].
26. Jaenson, T. G. T. 1991. The epidemiology of Lyme borreliosis. Parasitol. Today 7:39-45.
27. Jaulhac, B., R. Heller, F. X. Limbach, Y. Hansmann, D. Lipsker, H. Monteil, J. Sibilia, and Y. Piémont. 2000. Direct molecular typing of Borrelia burgdorferi sensu lato species in synovial samples from patients with Lyme arthritis. J. Clin. Microbiol. 38:1895-1900[Abstract/Free Full Text].
28. Karlsson, M., K. Hovind-Hougen, B. Svenungsson, and G. Stiernstedt. 1990. Cultivation and characterization of spirochetes from cerebrospinal fluid of patients with Lyme borreliosis. J. Clin. Microbiol. 28:473-479[Abstract/Free Full Text].
29. Kryuchechnikov, V. N., I. Korenberg, S. V. Scherbakov, Y. V. Kovalevsky, and M. L. Levin. 1988. Identification of Borrelia isolated in the USSR from Ixodes persulcatus schulze ticks. J. Microbiol. Epidemiol. Immunobiol. 12:41-44.
30. Kwok, S. 1990. Procedures to minimize PCR-product carry-over, p. 142-145. In M. A. Innis, D. H. Gelfand, J. J. Sninsky, and T. J. White (ed.), PCR protocols. Academic Press, Inc., San Diego, Calif.
31. Lebech, A.-M., K. Hansen, B. Wilske, and M. Thiesen. 1994. Taxonomic classification of 29 Borrelia burgdorferi strains isolated from patients with Lyme borreliosis: a comparison of five different phenotypic and genotypic typing schemes. Med. Microbiol. Immunol. 183:325-341[Medline].
32. Liebisch, G., B. Sohns, and W. Bautsch. 1998. Detection and typing of Borrelia burgdorferi sensu lato in Ixodes ricinus ticks attached to human skin by PCR. J. Clin. Microbiol. 36:3355-3358[Abstract/Free Full Text].
33. Liveris, D., S. Varde, R. Iyer, S. Koenig, S. Bittker, D. Cooper, D. McKenna, J. Nowakowski, R. B. Nadelman, G. P. Wormser, and I. Schwartz. 1999. Genetic diversity of Borrelia burgdorferi in Lyme disease patients as determined by culture versus direct PCR with clinical specimens. J. Clin. Microbiol. 37:565-569[Abstract/Free Full Text].
34. Marconi, R. T., and C. F. Garon. 1992. Development of polymerase chain reaction primer set for diagnosis of Lyme disease and for species-specific identification of Lyme disease isolates by 16 rRNA signature nucleotide analysis. J. Clin. Microbiol. 30:2830-2834[Abstract/Free Full Text].
35. Masuzawa, T., B. Wilske, T. Komikado, H. Suzuki, H. Kawabata, N. Sato, K. Muramatsu, N. Sato, E. Isogai, H. Isogai, R. C. Johnson, and Y. Yanagihara. 1996. Comparison of OspA serotypes for Borrelia burgdorferi sensu lato from Japan, Europe and North America. Microbiol. Immunol. 40:539-545[Medline].
36. Nilsson, I., and I. Andersson von Rosen. 1996. Serum antibodies against Borrelia afzelii, Borrelia burgdorferi sensu stricto and the 41-kilodalton flagellin in patients from a Lyme borreliosis endemic area: analysis by EIA and immunoblot. APMIS 104:907-914[Medline].
37. Nilsson, I., Å. Ljungh, P. Aleljung, and T. Wadström. 1997. Immunoblot assay for serodiagnosis of Helicobacter pylori infections. J. Clin. Microbiol. 35:427-432[Abstract].
38. Olsen, B., T. Jaenson, and S. Bergström. 1995. Prevalence of Borrelia burgdorferi sensu lato-infected ticks on migrating birds. Appl. Environ. Microbiol. 61:3082-3087[Abstract].
39. Picken, R. N., F. Strle, M. M. Picken, E. Ruzic-Sabljic, V. Maraspin, S. Lotric-Furlan, and J. Cimperman. 1998. Identification of three species of Borrelia burgdorferi (B. burgdorferi sensu stricto, B. garinii, and B. afzelii) among isolates from acrodermatitis chronica atrophicans lesions. J. Investig. Dermatol. 110:211-214[CrossRef][Medline].
40. Saint Giron, I., L. Gern, J. S. Gray, E. C. Guy, E. Korenberg, P. A. Nutall, S. G. Rijpkema, A. Schonberg, G. Stanek, and D. Postic. 1998. Identification of Borrelia burgdorferi sensu lato species in Europe. Zentbl. Bakteriol. 287:190-195.
41. Sigal, L. H., J. M. Zahradnik, P. Lavin, S. J. Patella, G. Bryant, R. Haselby, E. Hilton, M. Kunkel, D. Adler-Klein, T. Doherty, J. Evans, P. J. Molloy, A. L. Seidner, J. R. Sabetta, H. J. Simon, M. S. Klempner, J. Mays, D. Marks, and S. E. Malawista. 1998. A vaccine consisting of recombinant Borrelia burgdorferi outer-surface protein A to prevent Lyme disease. Recombinant Outer-Surface Protein A Lyme Disease Vaccine Study Consortium. N. Engl. J. Med. 339:216-222[Abstract/Free Full Text].
42. Steere, A. C., V. K. Sikand, F. Meurice, D. L. Parenti, E. Fikrig, R. T. Schoen, J. Nowakowski, C. H. Schmid, S. Laukamp, C. Buscarino, and D. S. Krause. 1998. Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. Lyme Disease Vaccine Study Group. N. Engl. J. Med. 339:209-215.
43. Stiernstedt, G., R. Gustavsson, M. Karlsson, B. Svenungsson, and B. Sköldenberg. 1988. Clinical manifestations and diagnosis of neuroborreliosis. Ann. N.Y. Acad. Sci. 539:46-55[CrossRef][Medline].
44. van Dam, A., H. Kuiper, K. Vos, A. Widjojokusumo, B. M. De Jongh, L. Spanjard, A. C. P. Ramselaar, M. D. Kramer, and J. Dankert. 1993. Different genospecies of Borrelia burgdorferi are associated with distinct clinical manifestations of Lyme borreliosis. Clin. Infect. Dis. 17:708-717[Medline].
45. Wang, G., A. P. Dam, and J. Dankert. 1999. Phenotypic and genetic characterization of a novel Borrelia burgdorferi sensu lato isolate from a patient with Lyme borreliosis. J. Clin. Microbiol. 37:3025-3028[Abstract/Free Full Text].
46. Welsh, J., C. Pretzman, D. Postic, I. Saint Giron, G. Baranton, and M. McClelland. 1992. Genomic fingerprinting by arbitrarily primed polymerase chain reaction resolves Borrelia burgdorferi into three distinct phyletic groups. Int. J. Syst. Bacteriol. 42:370-377[Abstract/Free Full Text].
47. Wilske, B., U. Busch, H. Eiffert, V. Fingerle, H. W. Pfister, D. Rößler, and V. Preac Mursic. 1996. Diversity of OspA and OspC among cerebrospinal fluid isolates of Borrelia burgdorferi sensu lato from patients with neuroborreliosis in Germany. Med. Microbiol. Immunol. 184:195-201[Medline].
48. Wilske, B., V. Preac-Mursic, U. B. Göbel, B. Graf, S. Jauris-Heipke, E. Soutschek, E. Schwab, and G. Zumstein. 1993. An OspA serotyping system for Borrelia burgdorferi based on reactivity with monoclonal antibodies and OspA sequence analysis. J. Clin. Microbiol. 31:340-350[Abstract/Free Full Text].

Journal of Clinical Microbiology, April 2001, p. 1294-1298, Vol. 39, No. 4
0095-1137/01/$04.00+0   DOI: 10.1128/JCM.39.4.1294-1298.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ornstein, K.
Right arrow Articles by Bergström, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ornstein, K.
Right arrow Articles by Bergström, S.

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Antimicrob. Agents Chemother. Clin. Microbiol. Rev.
Clin. Vaccine Immunol. ALL ASM JOURNALS